Roche Holding AG Logo

Roche Holding AG

RHHBY

(2.5)
Stock Price

34,52 USD

23.26% ROA

36.46% ROE

13.15x PER

Market Cap.

210.593.403.665,22 USD

124.99% DER

3.51% Yield

17.79% NPM

Roche Holding AG Stock Analysis

Roche Holding AG Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Roche Holding AG Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (47.34%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 Dividend Growth

The company's dividend growth has consistently increased every year in the last five years, indicating a strong track record of positive returns for investors.

4 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

5 DER

The stock maintains a fair debt to equity ratio (95%), indicating a reasonable balance between the money it owes and the ownership it possesses.

6 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (161) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 PBV

The stock's elevated P/BV ratio (6.76x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

10 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

11 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

Roche Holding AG Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Roche Holding AG Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Roche Holding AG Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Roche Holding AG Revenue
Year Revenue Growth
1998 24.662.000.000
1999 27.567.000.000 10.54%
2000 28.672.000.000 3.85%
2001 29.163.000.000 1.68%
2002 29.725.000.000 1.89%
2003 31.220.000.000 4.79%
2004 31.273.000.000 0.17%
2005 35.511.000.000 11.93%
2006 42.041.000.000 15.53%
2007 46.133.000.000 8.87%
2008 45.617.000.000 -1.13%
2009 49.051.000.000 7%
2010 47.473.000.000 -3.32%
2011 42.531.000.000 -11.62%
2012 45.499.000.000 6.52%
2013 46.780.000.000 2.74%
2014 47.462.000.000 1.44%
2015 48.145.000.000 1.42%
2016 50.576.000.000 4.81%
2017 53.299.000.000 5.11%
2018 56.846.000.000 6.24%
2019 61.466.000.000 7.52%
2020 58.323.000.000 -5.39%
2021 62.801.000.000 7.13%
2022 63.281.000.000 0.76%
2023 60.441.000.000 -4.7%
2024 119.392.000.000 49.38%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Roche Holding AG Research and Development Expenses
Year Research and Development Expenses Growth
1998 3.408.000.000
1999 3.782.000.000 9.89%
2000 3.950.000.000 4.25%
2001 3.893.000.000 -1.46%
2002 4.257.000.000 8.55%
2003 4.766.000.000 10.68%
2004 5.093.000.000 6.42%
2005 5.705.000.000 10.73%
2006 6.589.000.000 13.42%
2007 8.385.000.000 21.42%
2008 8.845.000.000 5.2%
2009 9.874.000.000 10.42%
2010 10.026.000.000 1.52%
2011 8.326.000.000 -20.42%
2012 9.552.000.000 12.84%
2013 9.270.000.000 -3.04%
2014 9.895.000.000 6.32%
2015 9.581.000.000 -3.28%
2016 11.532.000.000 16.92%
2017 11.292.000.000 -2.13%
2018 12.092.000.000 6.62%
2019 12.774.000.000 5.34%
2020 13.009.000.000 1.81%
2021 14.799.000.000 12.1%
2022 16.023.000.000 7.64%
2023 14.200.000.000 -12.84%
2024 25.072.000.000 43.36%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Roche Holding AG General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 7.827.000.000
1999 8.987.000.000 12.91%
2000 9.988.000.000 10.02%
2001 9.671.000.000 -3.28%
2002 9.833.000.000 1.65%
2003 10.297.000.000 4.51%
2004 10.408.000.000 1.07%
2005 11.913.000.000 12.63%
2006 2.542.000.000 -368.65%
2007 2.453.000.000 -3.63%
2008 2.332.000.000 -5.19%
2009 2.175.000.000 -7.22%
2010 2.874.000.000 24.32%
2011 2.342.000.000 -22.72%
2012 3.053.000.000 23.29%
2013 2.645.000.000 -15.43%
2014 3.843.000.000 31.17%
2015 2.727.000.000 -40.92%
2016 1.715.000.000 -59.01%
2017 3.425.000.000 49.93%
2018 5.258.000.000 34.86%
2019 4.118.000.000 -27.68%
2020 3.042.000.000 -35.37%
2021 3.329.000.000 8.62%
2022 2.891.000.000 -15.15%
2023 14.881.000.000 80.57%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Roche Holding AG EBITDA
Year EBITDA Growth
1998 6.444.000.000
1999 8.874.000.000 27.38%
2000 9.979.000.000 11.07%
2001 4.800.000.000 -107.9%
2002 2.855.000.000 -68.13%
2003 7.102.000.000 59.8%
2004 10.584.000.000 32.9%
2005 9.680.000.000 -9.34%
2006 14.281.000.000 32.22%
2007 17.210.000.000 17.02%
2008 16.476.000.000 -4.45%
2009 18.402.000.000 10.47%
2010 16.467.000.000 -11.75%
2011 16.367.000.000 -0.61%
2012 16.969.000.000 3.55%
2013 18.598.000.000 8.76%
2014 16.627.000.000 -11.85%
2015 17.062.000.000 2.55%
2016 17.892.000.000 4.64%
2017 16.802.000.000 -6.49%
2018 18.162.000.000 7.49%
2019 21.739.000.000 16.45%
2020 22.501.000.000 3.39%
2021 22.862.000.000 1.58%
2022 21.526.000.000 -6.21%
2023 18.657.000.000 -15.38%
2024 44.904.000.000 58.45%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Roche Holding AG Gross Profit
Year Gross Profit Growth
1998 16.761.000.000
1999 18.693.000.000 10.34%
2000 19.509.000.000 4.18%
2001 20.824.000.000 6.31%
2002 21.293.000.000 2.2%
2003 22.905.000.000 7.04%
2004 24.091.000.000 4.92%
2005 26.207.000.000 8.07%
2006 31.425.000.000 16.6%
2007 32.390.000.000 2.98%
2008 31.956.000.000 -1.36%
2009 34.436.000.000 7.2%
2010 34.180.000.000 -0.75%
2011 30.589.000.000 -11.74%
2012 33.324.000.000 8.21%
2013 34.832.000.000 4.33%
2014 34.081.000.000 -2.2%
2015 32.685.000.000 -4.27%
2016 34.396.000.000 4.97%
2017 35.120.000.000 2.06%
2018 39.577.000.000 11.26%
2019 43.115.000.000 8.21%
2020 42.146.000.000 -2.3%
2021 43.154.000.000 2.34%
2022 42.884.000.000 -0.63%
2023 44.084.000.000 2.72%
2024 88.864.000.000 50.39%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Roche Holding AG Net Profit
Year Net Profit Growth
1998 4.392.000.000
1999 5.764.000.000 23.8%
2000 8.647.000.000 33.34%
2001 3.697.000.000 -133.89%
2002 -4.026.000.000 191.83%
2003 3.069.000.000 231.18%
2004 6.606.000.000 53.54%
2005 5.923.000.000 -11.53%
2006 7.880.000.000 24.84%
2007 9.761.000.000 19.27%
2008 8.969.000.000 -8.83%
2009 7.784.000.000 -15.22%
2010 8.666.000.000 10.18%
2011 9.343.000.000 7.25%
2012 9.427.000.000 0.89%
2013 11.164.000.000 15.56%
2014 9.332.000.000 -19.63%
2015 8.863.000.000 -5.29%
2016 9.576.000.000 7.45%
2017 8.633.000.000 -10.92%
2018 10.500.000.000 17.78%
2019 13.497.000.000 22.2%
2020 14.295.000.000 5.58%
2021 13.930.000.000 -2.62%
2022 12.421.000.000 -12.15%
2023 11.498.000.000 -8.03%
2024 25.032.000.000 54.07%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Roche Holding AG Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 1
1999 1 0%
2000 1 100%
2001 1 0%
2002 -1 0%
2003 0 0%
2004 1 0%
2005 1 0%
2006 1 100%
2007 1 0%
2008 1 0%
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 2 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 2 0%
2019 2 0%
2020 2 50%
2021 2 0%
2022 2 -100%
2023 2 0%
2024 4 66.67%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Roche Holding AG Free Cashflow
Year Free Cashflow Growth
1998 1.336.000.000
1999 -686.000.000 294.75%
2000 1.514.000.000 145.31%
2001 2.948.000.000 48.64%
2002 -1.157.000.000 354.8%
2003 4.760.000.000 124.31%
2004 4.800.000.000 0.83%
2005 6.307.000.000 23.89%
2006 6.175.000.000 -2.14%
2007 7.263.000.000 14.98%
2008 8.620.000.000 15.74%
2009 13.658.000.000 36.89%
2010 11.332.000.000 -20.53%
2011 10.749.000.000 -5.42%
2012 12.599.000.000 14.68%
2013 12.918.000.000 2.47%
2014 12.596.000.000 -2.56%
2015 11.141.000.000 -13.06%
2016 9.856.000.000 -13.04%
2017 13.811.000.000 28.64%
2018 15.057.000.000 8.28%
2019 17.489.000.000 13.91%
2020 11.876.000.000 -47.26%
2021 16.427.000.000 27.7%
2022 13.863.000.000 -18.5%
2023 11.446.000.000 -21.12%
2024 3.095.000.000 -269.82%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Roche Holding AG Operating Cashflow
Year Operating Cashflow Growth
1998 3.617.000.000
1999 1.727.000.000 -109.44%
2000 3.916.000.000 55.9%
2001 5.088.000.000 23.03%
2002 982.000.000 -418.13%
2003 7.253.000.000 86.46%
2004 7.335.000.000 1.12%
2005 9.975.000.000 26.47%
2006 10.329.000.000 3.43%
2007 11.728.000.000 11.93%
2008 12.177.000.000 3.69%
2009 16.877.000.000 27.85%
2010 14.342.000.000 -17.68%
2011 12.954.000.000 -10.71%
2012 15.005.000.000 13.67%
2013 15.772.000.000 4.86%
2014 15.930.000.000 0.99%
2015 15.251.000.000 -4.45%
2016 15.001.000.000 -1.67%
2017 18.024.000.000 16.77%
2018 19.979.000.000 9.79%
2019 22.385.000.000 10.75%
2020 18.566.000.000 -20.57%
2021 20.976.000.000 11.49%
2022 18.415.000.000 -13.91%
2023 16.095.000.000 -14.41%
2024 3.957.000.000 -306.75%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Roche Holding AG Capital Expenditure
Year Capital Expenditure Growth
1998 2.281.000.000
1999 2.413.000.000 5.47%
2000 2.402.000.000 -0.46%
2001 2.140.000.000 -12.24%
2002 2.139.000.000 -0.05%
2003 2.493.000.000 14.2%
2004 2.535.000.000 1.66%
2005 3.668.000.000 30.89%
2006 4.154.000.000 11.7%
2007 4.465.000.000 6.97%
2008 3.557.000.000 -25.53%
2009 3.219.000.000 -10.5%
2010 3.010.000.000 -6.94%
2011 2.205.000.000 -36.51%
2012 2.406.000.000 8.35%
2013 2.854.000.000 15.7%
2014 3.334.000.000 14.4%
2015 4.110.000.000 18.88%
2016 5.145.000.000 20.12%
2017 4.213.000.000 -22.12%
2018 4.922.000.000 14.4%
2019 4.896.000.000 -0.53%
2020 6.690.000.000 26.82%
2021 4.549.000.000 -47.07%
2022 4.552.000.000 0.07%
2023 4.649.000.000 2.09%
2024 862.000.000 -439.33%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Roche Holding AG Equity
Year Equity Growth
1998 22.815.000.000
1999 30.001.000.000 23.95%
2000 32.036.000.000 6.35%
2001 33.867.000.000 5.41%
2002 25.773.000.000 -31.4%
2003 29.164.000.000 11.63%
2004 33.293.000.000 12.4%
2005 41.743.000.000 20.24%
2006 46.814.000.000 10.83%
2007 53.307.000.000 12.18%
2008 53.822.000.000 0.96%
2009 9.414.000.000 -471.72%
2010 11.662.000.000 19.28%
2011 14.482.000.000 19.47%
2012 16.728.000.000 13.43%
2013 21.241.000.000 21.25%
2014 21.558.000.000 1.47%
2015 23.300.000.000 7.48%
2016 26.402.000.000 11.75%
2017 29.007.000.000 8.98%
2018 30.366.000.000 4.48%
2019 35.867.000.000 15.34%
2020 39.773.000.000 9.82%
2021 28.345.000.000 -40.32%
2022 32.015.000.000 11.46%
2023 33.263.000.000 3.75%
2023 30.344.000.000 -9.62%
2024 32.876.000.000 7.7%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Roche Holding AG Assets
Year Assets Growth
1998 55.879.000.000
1999 70.431.000.000 20.66%
2000 69.535.000.000 -1.29%
2001 75.286.000.000 7.64%
2002 63.995.000.000 -17.64%
2003 59.486.000.000 -7.58%
2004 58.076.000.000 -2.43%
2005 69.365.000.000 16.27%
2006 74.414.000.000 6.79%
2007 78.183.000.000 4.82%
2008 76.089.000.000 -2.75%
2009 74.565.000.000 -2.04%
2010 61.020.000.000 -22.2%
2011 61.576.000.000 0.9%
2012 64.805.000.000 4.98%
2013 62.167.000.000 -4.24%
2014 75.641.000.000 17.81%
2015 75.763.000.000 0.16%
2016 76.819.000.000 1.37%
2017 76.676.000.000 -0.19%
2018 78.517.000.000 2.34%
2019 83.091.000.000 5.5%
2020 86.138.000.000 3.54%
2021 92.317.000.000 6.69%
2022 88.151.000.000 -4.73%
2023 90.468.000.000 2.56%
2023 84.370.000.000 -7.23%
2024 95.786.000.000 11.92%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Roche Holding AG Liabilities
Year Liabilities Growth
1998 33.064.000.000
1999 40.430.000.000 18.22%
2000 37.499.000.000 -7.82%
2001 41.419.000.000 9.46%
2002 38.222.000.000 -8.36%
2003 30.322.000.000 -26.05%
2004 24.783.000.000 -22.35%
2005 27.622.000.000 10.28%
2006 27.600.000.000 -0.08%
2007 24.876.000.000 -10.95%
2008 22.267.000.000 -11.72%
2009 65.151.000.000 65.82%
2010 49.358.000.000 -32%
2011 47.094.000.000 -4.81%
2012 48.077.000.000 2.04%
2013 40.926.000.000 -17.47%
2014 54.083.000.000 24.33%
2015 52.463.000.000 -3.09%
2016 50.417.000.000 -4.06%
2017 47.669.000.000 -5.76%
2018 48.151.000.000 1%
2019 47.224.000.000 -1.96%
2020 46.365.000.000 -1.85%
2021 63.972.000.000 27.52%
2022 56.136.000.000 -13.96%
2023 57.205.000.000 1.87%
2023 54.026.000.000 -5.88%
2024 62.910.000.000 14.12%

Roche Holding AG Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
13.97
Net Income per Share
2.5
Price to Earning Ratio
13.15x
Price To Sales Ratio
2.36x
POCF Ratio
10.51
PFCF Ratio
14.51
Price to Book Ratio
7.23
EV to Sales
2.72
EV Over EBITDA
7.97
EV to Operating CashFlow
12.15
EV to FreeCashFlow
16.66
Earnings Yield
0.08
FreeCashFlow Yield
0.07
Market Cap
210,59 Bil.
Enterprise Value
241,94 Bil.
Graham Number
15.97
Graham NetNet
-6.43

Income Statement Metrics

Net Income per Share
2.5
Income Quality
1.56
ROE
0.55
Return On Assets
0.11
Return On Capital Employed
0.26
Net Income per EBT
0.81
EBT Per Ebit
0.74
Ebit per Revenue
0.3
Effective Tax Rate
0.12

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.23
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.74
Operating Profit Margin
0.3
Pretax Profit Margin
0.22
Net Profit Margin
0.18

Dividends

Dividend Yield
0.04
Dividend Yield %
3.51
Payout Ratio
0.48
Dividend Per Share
1.57

Operating Metrics

Operating Cashflow per Share
3.12
Free CashFlow per Share
2.28
Capex to Operating CashFlow
0.27
Capex to Revenue
0.06
Capex to Depreciation
1.28
Return on Invested Capital
0.34
Return on Tangible Assets
0.23
Days Sales Outstanding
49.88
Days Payables Outstanding
61.67
Days of Inventory on Hand
122.69
Receivables Turnover
7.32
Payables Turnover
5.92
Inventory Turnover
2.98
Capex per Share
0.85

Balance Sheet

Cash per Share
1,38
Book Value per Share
5,16
Tangible Book Value per Share
0.87
Shareholders Equity per Share
4.54
Interest Debt per Share
5.84
Debt to Equity
1.25
Debt to Assets
0.38
Net Debt to EBITDA
1.03
Current Ratio
1.26
Tangible Asset Value
5,57 Bil.
Net Current Asset Value
-29,28 Bil.
Invested Capital
58196000000
Working Capital
7,03 Bil.
Intangibles to Total Assets
0.29
Average Receivables
12,17 Bil.
Average Payables
2,00 Bil.
Average Inventory
7945000000
Debt to Market Cap
0.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Roche Holding AG Dividends
Year Dividends Growth
2004 1
2005 1 0%
2006 1 0%
2007 1 100%
2008 2 50%
2009 1 -100%
2010 1 0%
2011 2 0%
2012 2 50%
2013 2 -100%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 1 0%
2021 1 0%
2022 1 0%
2023 1 0%
2024 2 0%

Roche Holding AG Profile

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.

CEO
Dr. Thomas Schinecker
Employee
103.605
Address
Konzern Hauptsitz
Basel, 4070

Roche Holding AG Executives & BODs

Roche Holding AG Executives & BODs
# Name Age
1 Dr. Thomas Schinecker
Chief Executive Officer
70
2 Dr. Nicolas Dunant
Head of Group Media Relations
70
3 Dr. Alan Hippe
Chief Financial & Information Officer
70
4 Ms. Cristina A. Wilbur
Chief People Officer
70
5 Dr. Bruno Eschli
Head of Investor Relations
70
6 Dr. Severin Schwan Ph.D.
Executive Chairman
70
7 Mr. Boris L. Zaitra
Head of Corporate Business Development
70
8 Ms. Barbara Schadler
Head of Group Communications
70
9 Ms. Claudia Bockstiegel
General Counsel
70
10 Ms. Pascale Schmidt
Chief Compliance Officer
70

Roche Holding AG Competitors

Sanofi Logo
Sanofi

SNY

(3.0)
AstraZeneca PLC Logo
AstraZeneca PLC

AZN

(3.0)
GSK plc Logo
GSK plc

GSK

(2.2)
Merck & Co., Inc. Logo
Merck & Co., Inc.

MRK

(2.2)
Novartis AG Logo
Novartis AG

NVS

(2.0)